People suffering from Parkinson's disease, cancer, and motor neurone disease could save money after three drugs were added to the Pharmaceutical Benefits Scheme.
The listing of the drug Adcetris will be broadened to treat a rare form of cancer.
Without a subsidy, patients could pay up to 300 thousand dollars per year for treatment with this drug.
More than eleven thousand people with Parkinson's disease are expected to benefit from the listing of the drug Xadago.
It would otherwise cost $1.400 per year.
The drug Teglutik is used to treat a form of Motor Neurone Disease.
More than 1,300 patients are expected to benefit from its listing on the scheme.
All three drugs will be able to be accessed from next month for $40.30 per script, or $6.50 per script for those with a concession card.
Share
